Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 220 participants.

Also called NCT02320669

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (enrolled count) (from the registry)
Sponsor
Seattle Children's Hospital (from the registry)
Registry
  • NCT NCT02320669
Other papers using this trial's data
  • Triiodothyronine Supplementation in Infants Undergoing Cardiopulmonary Bypass: A Randomized Controlled Trial Seminars in thoracic and cardiovascular surgery, 2023 DOI, PubMed 35093535

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02320669. Randomized; triple masking; primary purpose treatment. Start 2014-11 (registry gives no type); primary completion 2019-10 (actual). Results posted on 2024-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Acronym
TRICC-2
Intervention (Drug)
Triostat
Intervention (Drug)
Placebo
Lead sponsor
Seattle Children's Hospital (class: other)

Record details

Record id
cardio:ct-nct02320669
Content hash
a8d61e98479e90b4f9485f51fb6bbea4e371d4700a87b6d608daa65983bf321f